PURPOSE: The Src family of kinases may play a role in the development and progression of gastric cancer. We evaluated the activity and safety of saracatinib an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting Src kinases, in patients with metastatic or locally advanced gastric carcinoma. METHODS: Eligible patients who had received ≤1 prior line of chemotherapy for metastatic disease received saracatinib 175 mg/day of a 28 day cycle until progression. The primary endpoint was the objective response and/or prolonged stable disease rate (pSD ≥ 16 weeks). RESULTS: Ten patients with gastric carcinoma and 11 with adenocarcinoma of the gastroesophageal junction received a median of 2 cycles (range 1-10 cycles) of treatment per patient. 17 patients were evaluable for response. No objective response was seen. One patient experienced prolonged Stable disease (pSD). Three patients had SD and 13 progressive disease. Median overall survival was 7.8 months (95% CI, 3.9-12.2 months) and median time to progression was 1.8 months (95% CI: 1.5-1.9 months). Grade 3 events possibly related to saracatinib included: fatigue (2 patients), hypoxia (2) anemia (3) and lymphopenia (2). CONCLUSION: Saracatinib has insufficient activity as a single agent in patients with advanced gastric adenocarcinoma to warrant further investigation. Further development in gastric cancer would require rational drug combinations or identification of a tumor phenotype sensitive to Src inhibition.
PURPOSE: The Src family of kinases may play a role in the development and progression of gastric cancer. We evaluated the activity and safety of saracatinib an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting Src kinases, in patients with metastatic or locally advanced gastric carcinoma. METHODS: Eligible patients who had received ≤1 prior line of chemotherapy for metastatic disease received saracatinib 175 mg/day of a 28 day cycle until progression. The primary endpoint was the objective response and/or prolonged stable disease rate (pSD ≥ 16 weeks). RESULTS: Ten patients with gastric carcinoma and 11 with adenocarcinoma of the gastroesophageal junction received a median of 2 cycles (range 1-10 cycles) of treatment per patient. 17 patients were evaluable for response. No objective response was seen. One patient experienced prolonged Stable disease (pSD). Three patients had SD and 13 progressive disease. Median overall survival was 7.8 months (95% CI, 3.9-12.2 months) and median time to progression was 1.8 months (95% CI: 1.5-1.9 months). Grade 3 events possibly related to saracatinib included: fatigue (2 patients), hypoxia (2) anemia (3) and lymphopenia (2). CONCLUSION:Saracatinib has insufficient activity as a single agent in patients with advanced gastric adenocarcinoma to warrant further investigation. Further development in gastric cancer would require rational drug combinations or identification of a tumor phenotype sensitive to Src inhibition.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: N Takekura; W Yasui; K Yoshida; T Tsujino; H Nakayama; T Kameda; H Yokozaki; Y Nishimura; H Ito; E Tahara Journal: Int J Cancer Date: 1990-05-15 Impact factor: 7.396
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Primo N Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara Journal: Anticancer Drugs Date: 2009-03 Impact factor: 2.248
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Bostjan Humar; Ryuji Fukuzawa; Vanessa Blair; Anita Dunbier; Helen More; Amanda Charlton; Han Kwang Yang; Woo Ho Kim; Anthony E Reeve; Iain Martin; Parry Guilford Journal: Cancer Res Date: 2007-03-15 Impact factor: 12.701
Authors: Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green Journal: J Clin Invest Date: 2013-12-09 Impact factor: 14.808
Authors: John J Arcaroli; Kevin S Quackenbush; Rebecca W Powell; Todd M Pitts; Anna Spreafico; Marileila Varella-Garcia; Lynne Bemis; Aik Choon Tan; Jaclyn M Reinemann; Basel M Touban; Arvind Dasari; S Gail Eckhardt; Wells A Messersmith Journal: Clin Cancer Res Date: 2012-05-01 Impact factor: 12.531
Authors: Adam C Kaufman; Santiago V Salazar; Laura T Haas; Jinhee Yang; Mikhail A Kostylev; Amanda T Jeng; Sophie A Robinson; Erik C Gunther; Christopher H van Dyck; Haakon B Nygaard; Stephen M Strittmatter Journal: Ann Neurol Date: 2015-03-21 Impact factor: 10.422
Authors: S M Reddy; S Kopetz; J Morris; N Parikh; W Qiao; M J Overman; D Fogelman; I Shureiqi; C Jacobs; Z Malik; C A Jimenez; R A Wolff; J L Abbruzzese; G Gallick; C Eng Journal: Invest New Drugs Date: 2015-06-12 Impact factor: 3.850